Renhe Pharmacy Co.,Ltd

XSEC:000650 Stock Report

Market Cap: CN¥8.0b

Renhe PharmacyLtd Valuation

Is 000650 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000650 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000650 (CN¥5.77) is trading above our estimate of fair value (CN¥3.84)

Significantly Below Fair Value: 000650 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000650?

Other financial metrics that can be useful for relative valuation.

000650 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA5.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 000650's PE Ratio compare to its peers?

The above table shows the PE ratio for 000650 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.8x
300401 Zhejiang Garden BiopharmaceuticalLtd
28.7x34.7%CN¥8.2b
002550 Changzhou Qianhong BiopharmaLTD
26.8x16.7%CN¥7.9b
000597 Northeast Pharmaceutical Group
20.7xn/aCN¥7.2b
688526 Wuhan Keqian BiologyLtd
23.1x25.3%CN¥6.9b
000650 Renhe PharmacyLtd
18.1xn/aCN¥8.0b

Price-To-Earnings vs Peers: 000650 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the peer average (24.8x).


Price to Earnings Ratio vs Industry

How does 000650's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 000650 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the CN Pharmaceuticals industry average (28.4x).


Price to Earnings Ratio vs Fair Ratio

What is 000650's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000650 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 000650's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies